ADAMTS13 and thrombotic thrombocytopenic purpura: The cornerstone of first-line therapy for acute TTP is based on therapeutic plasma exchange supplying the patient’s deficient ADAMTS13, performed daily until hemolysis and features related to organ involvement have resolved and the platelet count has stably recovered.